Targeting coagulation mediators in head and neck cancer

Rohith Jesudas; Qinghua Zeng; Danielle M. Garshott; Nicholas Yoo; Andrew M. Fribley; Jordan A. Shavit; Michael U. Callaghan

doi:10.1007/978-3-319-27647-2_11

Targeting coagulation mediators in head and neck cancer

Rohith Jesudas, Qinghua Zeng, Danielle M. Garshott, Nicholas Yoo, Andrew M. Fribley, Jordan A. Shavit, Michael U. Callaghan

COLLEGE OF MEDICINE

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

This chapter examines the role of the coagulation system in cancer. While the role of a prothrombotic state was linked to cancer development many years ago, effective targeting of mediators of coagulation is not yet an element of cancer therapy. In the last decade, multiple novel anticoagulants have been approved for use in the prevention or treatment of thrombotic conditions. The presence of a larger armamentarium of medications with fewer bleeding side effects makes them suitable adjuncts in the multimodal treatment of cancer.

Original language	English
Title of host publication	Targeting Oral Cancer
Publisher	Springer International Publishing
Pages	263-281
Number of pages	19
ISBN (Electronic)	9783319276472
ISBN (Print)	9783319276458
DOIs	https://doi.org/10.1007/978-3-319-27647-2_11
State	Published - Jan 1 2016

Keywords

Coagulation
Fibrinogen
HNSCC
Head and neck cancer
Hemostasis
Metastasis
OSCC
Oral cancer
Thrombin
Thrombosis
Von Willebrand factor

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/978-3-319-27647-2_11

Cite this

@inbook{398483303f9f4dafb46f5178d4125e43,

title = "Targeting coagulation mediators in head and neck cancer",

abstract = "This chapter examines the role of the coagulation system in cancer. While the role of a prothrombotic state was linked to cancer development many years ago, effective targeting of mediators of coagulation is not yet an element of cancer therapy. In the last decade, multiple novel anticoagulants have been approved for use in the prevention or treatment of thrombotic conditions. The presence of a larger armamentarium of medications with fewer bleeding side effects makes them suitable adjuncts in the multimodal treatment of cancer.",

keywords = "Coagulation, Fibrinogen, HNSCC, Head and neck cancer, Hemostasis, Metastasis, OSCC, Oral cancer, Thrombin, Thrombosis, Von Willebrand factor",

author = "Rohith Jesudas and Qinghua Zeng and Garshott, {Danielle M.} and Nicholas Yoo and Fribley, {Andrew M.} and Shavit, {Jordan A.} and Callaghan, {Michael U.}",

note = "Publisher Copyright: {\textcopyright} Springer International Publishing Switzerland 2016.",

year = "2016",

month = jan,

day = "1",

doi = "10.1007/978-3-319-27647-2_11",

language = "English",

isbn = "9783319276458",

pages = "263--281",

booktitle = "Targeting Oral Cancer",

publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Targeting coagulation mediators in head and neck cancer

AU - Jesudas, Rohith

AU - Zeng, Qinghua

AU - Garshott, Danielle M.

AU - Yoo, Nicholas

AU - Fribley, Andrew M.

AU - Shavit, Jordan A.

AU - Callaghan, Michael U.

N1 - Publisher Copyright: © Springer International Publishing Switzerland 2016.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - This chapter examines the role of the coagulation system in cancer. While the role of a prothrombotic state was linked to cancer development many years ago, effective targeting of mediators of coagulation is not yet an element of cancer therapy. In the last decade, multiple novel anticoagulants have been approved for use in the prevention or treatment of thrombotic conditions. The presence of a larger armamentarium of medications with fewer bleeding side effects makes them suitable adjuncts in the multimodal treatment of cancer.

AB - This chapter examines the role of the coagulation system in cancer. While the role of a prothrombotic state was linked to cancer development many years ago, effective targeting of mediators of coagulation is not yet an element of cancer therapy. In the last decade, multiple novel anticoagulants have been approved for use in the prevention or treatment of thrombotic conditions. The presence of a larger armamentarium of medications with fewer bleeding side effects makes them suitable adjuncts in the multimodal treatment of cancer.

KW - Coagulation

KW - Fibrinogen

KW - HNSCC

KW - Head and neck cancer

KW - Hemostasis

KW - Metastasis

KW - OSCC

KW - Oral cancer

KW - Thrombin

KW - Thrombosis

KW - Von Willebrand factor

UR - http://www.scopus.com/inward/record.url?scp=85017046829&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-27647-2_11

DO - 10.1007/978-3-319-27647-2_11

M3 - Chapter

AN - SCOPUS:85017046829

SN - 9783319276458

SP - 263

EP - 281

BT - Targeting Oral Cancer

PB - Springer International Publishing

ER -

Targeting coagulation mediators in head and neck cancer

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this